Blood biologic markers of stroke: Improved management, reduced cost?

被引：11

作者：

Baird A.E. ^{[1
]}

机构：

[1] Stroke Neuroscience Unit, NINDS/NIH, Bethesda, MD 20892-1294

来源：

Current Atherosclerosis Reports | 2006年 / 8卷 / 4期

关键词：

Ischemic Stroke; Stroke Risk; Chronic Granulomatous Disease; Stroke Recurrence; Systolic Blood Pressure Level;

D O I：

10.1007/s11883-006-0003-2

中图分类号：

学科分类号：

摘要：

Identifying blood biomarkers may be of particular value in neurologic disorders such as stroke because of the difficulty in directly studying the brain and its blood vessels. Markers of brain injury, inflammation, excitotoxicity, and oxidative damage have been evaluated for their value in stroke diagnosis, treatment, and management, but none have proved to be sensitive or specific enough for routine clinical use. However, new cellular and molecular profiling approaches using the peripheral blood offer the potential for identifying panels of genes and proteins by increasing specificity while maintaining sensitivity. Furthermore, the first biomarker for predicting stroke risk associated with atherosclerosis (lipoprotein-associated phospholipase A2) was recently approved by the United States Food and Drug Administration. The ultimate aim for stroke biomarkers is to develop rapid, easy to use, widely available, and inexpensive diagnostic tests that can be used in the clinic and in clinical trials. Copyright © 2006 by Current Science Inc.

引用

页码：267 / 275

页数：8

共 50 条

[41]

Nadar S.K., Lip G.Y., Lee K.W., Blann A.D., Circulating endothelial cells in acute ischaemic stroke, Thromb Haemost, 94, pp. 707-712, (2005)

[42]

Nadareishvili Z.G., Li H., Wright V., Et al., Elevated proinflammatory CD4+CD28- lymphocytes and stroke recurrence and death, Neurology, 63, pp. 1446-1451, (2004)

[43]

Garlichs C.D., Kozina S., Fateh-Moghadam S., Et al., Upregulation of CD40-CD40 ligand (CD154) in patients with acute cerebral ischemia, Stroke, 34, pp. 1412-1418, (2003)

[44]

Paczkowska E., Larysz B., Rzeuski R., Et al., Human hematopoietic stem/progenitor-enriched CD34(+) cells are mobilized into peripheral blood during stress related to ischemic stroke or acute myocardial infarction, Eur J Haematol, 75, pp. 461-467, (2005)

[45]

Elkind M., Coates A., Tai W., Sacco R.L., Lipoprotein-associated phospholipase A2 and C-reactive protein as predictors of stroke recurrence and death: The Northern Manhattan Stroke Study, Stroke, 37, pp. 625-626, (2006)

[46]

Libby P., Inflammation in atherosclerosis, Nature, 420, pp. 868-874, (2002)

[47]

Ballantyne C.M., Hoogeveen R.C., Bang H., Et al., Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study, Arch Intern Med, 165, pp. 2479-2484, (2005)

[48]

Di Napoli M., Schwaninger M., Cappelli R., Et al., Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: A statement for health care professionals from the CRP Pooling Project members, Stroke, 36, pp. 1316-1329, (2005)

[49]

Smith Jr. S.C., Anderson J.L., Cannon III R.O., Et al., CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: Report from the clinical practice discussion group, Circulation, 110, (2004)

[50]

Ridker P.M., Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Rationale and design of the JUPITER trial, Circulation, 108, pp. 2292-2297, (2003)

← 1 2 3 4 5 →